Category: C. diff infections

  • Pfizer’s seeks silver lining in failed C. diff vaccine trial

    Pfizer’s vaccine for Clostridium difficile (C. diff) looks like it may join a growing list of candidates that have been shelved or delayed, after the shot failed to meet its primary objective in a phase 3 trial. The pharma company was quick to point out however that the CLOVER trial of PF-06425090 was undermined by […]

  • Nestle gets closer to Seres, pledging $525m for microbiome C. diff drug

    Swiss food giant Nestle has firmed up its five-year-old alliance with US microbiome specialist Seres, paying $175 million upfront for North American co-marketing rights to its lead drug for Clostridium difficile infections. Under the terms of the new deal, Nestle’s Health Sciences unit will pay Seres another $125 million if the FDA approves the drug […]